Company intelligence / Profile preview

Nanotein Technologies

Berkeley, California, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Nanotein has demonstrated advanced protein-nanoparticle technology for T cell and NK cell activation and expansion; products currently available for research use, with GMP versions pending launch.

Therapeutic areas: OncologyHematologyImmunology
Modalities: ProteinNanoparticleBiologic
Industry: Biotech

Partnerships

Akron Bio (cGMP manufacturing partner)Polaris Group (major investor and manufacturing partner)

Beyond the preview

Go deeper on Nanotein Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanotein Technologies.

Explore the full profile